
    
      INT230-6 is comprises a novel cell penetration and diffusion excipient with cisplatin and
      vinblastine in an aqueous liquid form. breast cancer patients awaiting surgery. In a 2:1
      randomization, patients will receive INT230-6 versus no treatment once weekly for 3 weeks
      (Days 1,8,15) prior to breast surgery (2-7 days later). There is no placebo in this trial.
    
  